Skip to main content
2024 CNSF Congress Main banner
Neuro|News Annual Edition
Final Program


Calendar-of-Events
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Society Mini-Platforms

Session: Adult Neurology (CNS) Mini-Platforms - A

A.6 James Perry - INDIGO: a global, randomized, double-blinded, Phase 3 study of vorasidenib versus placebo in patients with grade 2 glioma with an IDH1/2 mutation (mIDH1/2)

Friday, May 24, 2024
8:00 AM – 9:00 AM EST
Location: MM: BC